Investing.com - Financial Markets Worldwide
Open in App

Renascience Inc (4889)

Tokyo
Currency in JPY
1,193.00
+41.00(+3.56%)
Closed·

4889 Income Statement

Period Ending:
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
2026
31/03
Total Revenues
aa.aaaa.aa13910019413268
Total Revenues Growth
aa.aaaa.aa-33.49%-28.06%+94%-31.96%-48.48%
Cost Of Revenues
aa.aaaa.aa59-2944
Gross Profit
aa.aaaa.aa8010016512864
Gross Profit Growth
aa.aaaa.aa-55.56%+25%+65%-22.42%-50%
Gross Profit Margin %
aa.aaaa.aa57.55%100%85.05%96.97%94.12%
Other Operating Expenses, Total
aa.aaaa.aa291434417307421
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
aa.aaaa.aa+9.81%+49.14%-3.92%-26.38%+37.13%
aa.aaaa.aa82235236132201
aa.aaaa.aa193185167159197
aa.aaaa.aa1313131623
Operating Income
aa.aaaa.aa-211-334-252-179-357
Operating Income Growth
aa.aaaa.aa-148.24%-58.29%+24.55%+28.97%-99.44%
EBIT Margin %
aa.aaaa.aa-151.8%-334%-129.9%-135.61%-525%
Net Interest Expenses
aa.aaaa.aa-5---3
Net Interest Expenses Growth
aa.aaaa.aa+28.57%----
Interest Expense, Total
aa.aaaa.aa-5----
Interest And Investment Income
aa.aaaa.aa----3
Other Non Operating Expenses, Total
aa.aaaa.aa-26--1054
EBT, Excl. Unusual Items
aa.aaaa.aa-242-334-253-179-300
Gain (Loss) On Sale Of Assets
aa.aaaa.aa-----
Other Unusual Items, Total
aa.aaaa.aa-11--4322-
EBT, Incl. Unusual Items
aa.aaaa.aa-253-334-257143-300
EBT, Incl. Unusual Items Growth
aa.aaaa.aa-153%-32.02%+23.05%+155.64%-309.79%
EBT, Incl. Unusual Items Margin
aa.aaaa.aa-182.01%-334%-132.47%108.33%-441.18%
Income Tax Expense
aa.aaaa.aa111301
Net Income to Company
aa.aaaa.aa-254-335-258113-301
Minority Interest
aa.aaaa.aa-----
Net Income
aa.aaaa.aa-254-335-258113-301
Net Income Growth
aa.aaaa.aa-154%-31.89%+22.99%+143.8%-366.37%
Net Income Margin %
aa.aaaa.aa-182.73%-335%-132.99%85.61%-442.65%
Preferred Dividend and Other Adjustments
aa.aaaa.aa-----
Net Income to Common Excl. Extra Items
aa.aaaa.aa-254-335-258113-301
Basic EPS - Continuing Operations
aa.aaaa.aa-22.3-26.35-20.38.89-23.37
Basic EPS - Continuing Operations Growth
aa.aaaa.aa-118.99%-18.17%+22.99%+143.8%-362.93%
Diluted EPS - Continuing Operations
aa.aaaa.aa-22.3-26.35-20.38.89-23.37
Diluted EPS - Continuing Operations Growth
aa.aaaa.aa-118.99%-18.17%+22.99%+143.8%-362.93%
Basic Weighted Average Shares Outstanding
aa.aaaa.aa11.3912.7112.7112.7112.88
Diluted Weighted Average Shares Outstanding
aa.aaaa.aa11.3912.7112.7112.7112.88
Dividend Per Share
aa.aaaa.aa-----
Dividend Per Share Growth
aa.aaaa.aa-----
EBITDA
aa.aaaa.aa-208-333-251-178-
EBITDA Growth
aa.aaaa.aa--60.1%+24.62%+29.08%-
EBITDA Margin %
aa.aaaa.aa-149.64%-333%-129.38%-134.85%-
EBIT
aa.aaaa.aa-211-334-252-179-357
* In Millions of JPY (except for per share items)

FAQ

What was Renascience’s revenue at year end?

At the end of the last reported fiscal year, Renascience (4889) recorded total revenue of 68.00 million JPY.

How much revenue did Renascience report in the most recent quarter?

In its most recent quarterly earnings report, Renascience posted revenue of 10.00 million JPY.

What was Renascience’s net income for the year?

For the full year, Renascience reported net income of -301.00 million JPY.

How much net income did Renascience post in the last quarter?

In the most recent quarter, Renascience (4889) posted net income of -82.00 million JPY.

What was Renascience’s gross profit for the year?

Gross profit for the year was reported at 64.00 million JPY.

How much gross profit did Renascience generate last quarter?

Renascience recorded gross profit of 8.00 million JPY in its latest quarterly report.

What was Renascience’s annual operating income?

For the full year, Renascience (4889) reported operating income of -357.00 million JPY.

What was Renascience’s operating income last quarter?

Quarterly operating income was -82.00 million JPY.

What is Renascience’s most recent gross profit margin?

The latest reported gross profit margin for Renascience (4889) is 80.00% million JPY.

What is Renascience’s most recent net income margin?

Net income margin based on recent financials is -820.00% million JPY.

What is Renascience’s most recent EBIT margin?

Renascience reported an EBIT margin of -820.00% million JPY based on current figures.

How did Renascience’s revenue change compared to the previous quarter?

Revenue changed by -64.29% million JPY compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Renascience?

In the latest quarter, gross profit changed by -72.41% million JPY from the previous quarter.
Install Our App
Follow us
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.